膀胱癌是一种全球流行的恶性肿瘤，其发病率和预后均表现出显着的性别差异。尽管治疗方法取得了长足进步，但耐药性的严峻挑战仍然存在。膀胱癌的基因组景观以复杂的克隆异质性为特征，成为促进这种耐药性的关键决定因素。克隆进化封装了肿瘤细胞亚群随时间的动态转变，与耐药性状的出现有关。在这篇综述中，我们阐明了克隆进化在膀胱癌中的作用的当代见解，阐明了它作为肿瘤发生、疾病进展和治疗耐药性的巨大障碍的驱动因素的影响。版权所有 © 2024。由爱思唯尔有限公司出版。

Bladder cancer stands as a prevalent global malignancy, exhibiting notable sex-based variations in both incidence and prognosis. Despite substantial strides in therapeutic approaches, the formidable challenge of drug resistance persists. The genomic landscape of bladder cancer, characterized by intricate clonal heterogeneity, emerges as a pivotal determinant in fostering this resistance. Clonal evolution, encapsulating the dynamic transformations within subpopulations of tumor cells over time, is implicated in the emergence of drug-resistant traits. Within this review, we illuminate contemporary insights into the role of clonal evolution in bladder cancer, elucidating its influence as a driver in tumor initiation, disease progression, and the formidable obstacle of therapy resistance.Copyright © 2024. Published by Elsevier Ltd.